Biopharmaceuticals is one of Baoshan District’s four leading industries and a pillar industry that safeguards public health and well-being.In recent years, Baoshan has closely aligned with the strategic positioning of the “Northern Transformation,” fully advancing the construction of the “main hub of the Science and Technology Innovation Center.” With the development of the North Shanghai Biopharmaceutical Industrial Park as its core, the district has continuously strengthened efforts in high-end biopharmaceuticals, R&D and manufacturing of high-end medical devices, high-end medical services, and biopharmaceutical production-related services. As a result, the biopharmaceutical industry has experienced rapid growth, establishing the brand of “By the Shores of Meilan Lake, Global Pharmaceutical Valley.”From January to September of this year, the output value of Baoshan’s biopharmaceutical industry grew by 18.7% year-on-year, ranking among the highest in the city. Over the past two years, the industry has achieved an average annual growth rate of 71%. Last year, industrial fixed-asset investment in the North Shanghai Biopharmaceutical Industrial Park surged by 430%. The number of biopharmaceutical enterprises in the district has nearly doubled annually, rising from just over 100 in 2020 to nearly 400 today.

　　Cluster-Based Development: Forging a New Platform

　　The sector has evolved from an initial state of scarcity in large-scale and strong enterprises with a scattered layout to the current formation of a leading group and the emergence of a long-tail effect.In the drug R&D and manufacturing sector, leading enterprises such as Fosun and Shanghai Pharmaceuticals have expanded their presence. For instance, the inhalable COVID-19 vaccine produced by Shanghai Pharmaceuticals’ CanSino has recently been launched, while heavyweight “new forces” like Baoji Pharmaceutical and Drug Ranch are rapidly developing in Baoshan. In the mRNA and stem cell CAR-T fields—which have gained significant momentum over the past two years—leading companies like Aibo and Blue Magpie have successively established operations, while Hanshi and U-Cardi have already broken ground.In the CRO/CDMO sector, Medix and Lutu Technology have gathered in Meilan Lake; additionally, Baoshan District has attracted a number of star enterprises in the fields of synthetic biology and precision medicine. In the “2021 China Top 30 New Technology Pharmaceutical Companies Innovation Ranking,” Baoshan-based companies secured four spots.

　　Platform-Based Integration to "Strengthen Core Competencies"

　　Spanning 5.31 square kilometers, the North Shanghai Biomedical Industrial Park is one of the city’s “1+5” specialty industrial parks. This year, Baoshan District added a 1,275-mu vaccine zone, which was approved as the city’s only “Shanghai Innovative Vaccine Science and Technology Park.” The medical device zone, which has taken shape, is being developed into the “Shanghai High-End Medical Diagnostic and Treatment Equipment Industry Innovation Base,” building a platform-based closed-loop ecosystem around the industrial chain.A new batch of specialized facilities—including Guosheng Industrial Investment’s Baoshan Pharma Valley, Tianrui JinMAX Science and Technology Park, and Jinqiao Beijiao Industrial Park—will release an additional 320,000 square meters of industrial space. The clustering effect is evident: even before the completion of Phase I of Guosheng Baoshan Pharma Valley, its occupancy rate has already reached 90%.

　　Chain-Based Services to "Strengthen the Foundation"

　　Baoshan District took the lead in the city by establishing a district-level leading group for the development of the biopharmaceutical industry. It has successively introduced innovative measures such as “start construction immediately upon land acquisition,” the “100-day parallel service” for land management, and having the “top leader” serve as the “chief facilitator.” For example, Shanghai Pharmaceutical CanSino completed its production line construction in just three months, with Baoshan once again demonstrating the “Shanghai Speed” through its actions.Strategic partnerships have been established with the Shanghai Municipal Drug Administration and the Shanghai Stock Exchange to build specialized institutions in Baoshan, such as the Shanghai Biopharmaceutical Product Registration Guidance Service Station and the Shanghai Science and Technology Innovation Financial Service Center, providing professional and financial support to drive industrial development.

　　Targeted Support as a “Springboard”

　　We are effectively implementing a combination of the “30 Measures for Science and Technology Innovation” and Baoshan District’s specialized biopharmaceutical policies, allocating no less than 1 billion yuan in fiscal funds annually to foster the development of key industries.This year, Baoshan revised and launched Version 2.0 of its district-level biopharmaceutical special policies, making significant adjustments to the original support measures. Covering the entire biopharmaceutical industry chain, the overall level of support ranks among the “top tier” nationwide. By serving enterprises throughout their entire lifecycle and acting as a “partner” in their growth, Baoshan is helping companies accelerate their development.

　　Source: Shanghai Baoshan